Biomarin Pharmaceutical Inc. (BMRN)
NASDAQ · Healthcare
Biomarin Pharmaceutical Inc. EBITDA 2008–2025
Biomarin Pharmaceutical Inc. annual/quarterly ebitda history and growth rate from 2008 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Biomarin Pharmaceutical Inc. ebitda for the quarter ending March 31, 2026 was 146.1 M, a 40.62% decrease year-over-year.
- Biomarin Pharmaceutical Inc. ebitda for the twelve months ending March 31, 2026 was 596.6 M, a 88.13% increase year-over-year.
- Biomarin Pharmaceutical Inc. annual ebitda for 2025 was 489.0 M, a 15.78% decrease from 2024.
- Biomarin Pharmaceutical Inc. annual ebitda for 2024 was 580.6 M, a 100.11% increase from 2023.
- Biomarin Pharmaceutical Inc. annual ebitda for 2023 was 290.2 M, a 10.35% increase from 2022.
- Biomarin Pharmaceutical Inc. annual ebitda for 2022 was 262.9 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Biomarin Pharmaceutical Inc. EBITDA — FAQ
Biomarin Pharmaceutical Inc. (BMRN) ebitda over the last 18 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see BMRN's ebitda history?
The chart and table above show Biomarin Pharmaceutical Inc.'s ebitda by year and by quarter, including the growth rate.